TriviumVet work with an extensive network of research partners and academic institutions across the globe.
We have a number of clinical trials open for recruitment which are detailed below:
Our feline Rapamycin product also being evaluated in feline HCM proof-of-concept trials taking place in UC Davis, California and North Carolina State, NC.
RECRUITMENT CLOSED (email firstname.lastname@example.org if you would like to receive the results of this trial once they are published)
TriviumVet is collaborating with leading cardiologists, Dr Sonya Gordon (Texas A&M University) and Dr Ryan Fries (University of Illinois), to evaluate the effectiveness of RapaVet™ in client-owned dogs with DCM.
TriviumVet are also supplying RapaVet™ to the Morris Animal Foundation Research into sub valvular aortic stenosis, the most common congenital heart defect in dogs
A canine trial to demonstrate the tool’s responsiveness to treatment effects of a neuroactive painkiller in an interventional crossover study led by Profs Natasha Olby of North Carolina State University is underway.
RECRUITMENT OPENING SOON
OmepraVet™ is a 10mg delayed-release capsule which has been demonstrated to be effective in a laboratory study using a canine disease model of induced gastric ulceration run in Texas A&M University. The product is in the final stages of regulatory review with the Center for Veterinary Medicine at FDA.
The TriviumVet gastric diagnostic device is entering clinical proof of concept trials in NC State University led by Dr. Katie Tolbert.
Chronic Kidney Disease is a significant issue in both human and cats and indicative of age-related decline in kidney function. The feline CKD study taking place at The Ohio State University is assessing our proprietary Rapamycin formulation in CKD in cats. The results of this study will be an exciting milestone in understanding the disease and developing a new veterinary treatment.